5 Key Takeaways from MAGIE 2021
August 30, 2021
The company has both a new corn herbicide and seed treatment coming next year.
Agricultural giant is hopeful acquisition will further the company’s autonomous vehicle plans.
The company will offer alternatives, with glyphosate use remaining for the agricultural industry.
It appears that glyphosate, while remaining an important tool for agriculture, just might disappear from the residential market.
For many companies, just “getting through” the past 18 months has been a major accomplishment.
Don’t ignore those voices telling you to “do better” because time is short, or the pressure is high, or it’s the end of the day.
Country’s president had pledged to end herbicide’s use by 2020, without success.
Excessive heat in many parts of the country is now taking a toll on many of the nation’s growers.
A panel of countries has determined the science saying the popular herbicide is “safe” is “sound.”
Creating a “try before you buy” scenario reduces pressure on cooperative managers to merge if cultural differences stymie progress, or previously unseen roadblocks emerge.
Following a virtual event in 2020, the Midwest AG Industries Exposition (MAGIE) will be back in-person for its anniversary show.
There is plenty of interest in carbon credits, but many questions for ag retailers remain.
Multiple states have now dropped or loosened mask/social distancing restrictions, which should mean in-person events can finally take place.
Editor Eric Sfiligoj offers his insight into what the U.S. ag retail landscape will look like in four years.
Strong demand has pushed steel prices to record highs, worrying equipment makers in the process.
Ninth Court of Appeals tells EPA to decide on active ingredient’s market status within the next two months.
Some ag retailers are warning grower-customers that the products they want for the 2021 growing season might be unavailable.
Dealerships and cooperative keep looking at combining forces to stay profitable in today’s agriculture marketplace.
After dropping FeXapan, the company has now nixed its pending in-development product as well.